Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Operating Income (2020 - 2025)

Historic Operating Income for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $22.9 million.

  • Pharming's Operating Income rose 45664.56% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 12972.94%. This contributed to the annual value of -$8.6 million for FY2024, which is 6003.34% down from last year.
  • Latest data reveals that Pharming reported Operating Income of $22.9 million as of Q3 2025, which was up 45664.56% from $3.8 million recorded in Q2 2025.
  • Pharming's 5-year Operating Income high stood at $6.3 billion for Q1 2021, and its period low was -$6.2 billion during Q2 2021.
  • Moreover, its 5-year median value for Operating Income was -$1.7 million (2021), whereas its average is $1.5 million.
  • Within the past 5 years, the most significant YoY rise in Pharming's Operating Income was 56480.42% (2022), while the steepest drop was 15930.23% (2022).
  • Pharming's Operating Income (Quarter) stood at $17.2 million in 2021, then plummeted by 159.3% to -$10.2 million in 2022, then soared by 47.19% to -$5.4 million in 2023, then tumbled by 60.03% to -$8.6 million in 2024, then surged by 365.25% to $22.9 million in 2025.
  • Its Operating Income was $22.9 million in Q3 2025, compared to $3.8 million in Q2 2025 and -$7.0 million in Q1 2025.